Overview of Stahist AD

Here is a quick overview of Stahist AD, detailing its key attributes and composition.

Property	Description
Active ingredient	Chlorcyclizine	Pseudoephedrine
Form	Oral tablet (or liquid)
Pharmacological class	Upper Respiratory Combination
Common purpose	Relief from cold and allergy symptoms
Origin	Synthetic (chemically manufactured)

What Type of Medicine is Stahist AD?

Stahist AD is a synthetic oral medication classified as an Upper Respiratory Combination drug, meaning it combines two different types of active ingredients to treat simultaneous symptoms of colds and allergies. This dual-component classification reflects a standard approach in medical practice for managing multi-symptom illness. Because it is an oral medication, its effects are systemic, meaning the ingredients are absorbed into the bloodstream to treat symptoms across the body, offering a comprehensive solution for patients experiencing widespread congestion and irritation.

What Active Ingredients Make Up Stahist AD?

Stahist AD utilizes a dual-action formula based on an antihistamine, Chlorcyclizine hydrochloride, and a decongestant, Pseudoephedrine hydrochloride. The antihistamine component, Chlorcyclizine, is intended to control the allergic response, which helps reduce symptoms like sneezing and watery eyes. The decongestant component, Pseudoephedrine, is used for reducing nasal stuffiness and congestion. This decongestant helps by temporarily constricting blood vessels in the nose. This blend is often utilized when both inflammatory (allergy) and mechanical (congestion) symptoms are present.

What is the General Purpose of This Combination Drug?

The overall purpose of Stahist AD is to offer effective, multi-symptom relief by simultaneously drying up secretions and clearing nasal congestion using its two primary components. This makes it a comprehensive solution intended to manage the discomfort caused by both histamine release and vascular congestion. The combination is formulated to streamline treatment for patients who need continuous relief from multiple issues, such as those with chronic seasonal allergies or severe common cold symptoms.

What side effects are possible with Stahist AD?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics for this combination product, based strictly on government regulatory labeling. The profile is defined by the effects of both the antihistamine and the decongestant components.

Adverse Reactions by System-Organ Class

The most frequently reported adverse reactions affect several body systems. Due to the dual nature of the active ingredients, the effects can be opposing. Nervous System Disorders include both sedation and drowsiness (from the antihistamine) and nervousness, restlessness, and insomnia (from the decongestant). Cardiovascular Disorders include documented effects such as tachycardia (rapid heartbeat), palpitations, and elevated blood pressure (hypertension).

Other commonly documented effects, often referred to as anticholinergic effects, fall under Gastrointestinal and Renal/Urinary Disorders and include dry mouth, dry nose, and difficulty or inability to urinate.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation notes potential for serious events, which, while rare, are clinically significant. These include severe hypertensive crisis, cardiovascular collapse, and the risk of seizures. Specific constraints are officially documented: the medicine is contra-indicated for use in patients with severe uncontrolled high blood pressure, severe coronary artery disease, or those concurrently taking Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping an MAOI.

Population-Specific Safety Notes

The label specifies that older adults may be more susceptible to adverse effects, including confusion, dizziness, and increased risk of urinary retention. Conversely, in some pediatric patients, the medicine may cause excitation rather than sedation. Furthermore, the characteristic effect of drowsiness may be more prominent shortly after administration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the potential for serious manifestations following an overdose of Stahist AD, which is a combination of an antihistamine and a decongestant.

Documented Overdose Presentations

Overdose presentations documented in labeling primarily affect the Central Nervous System and Cardiovascular System. Manifestations may include CNS stimulation leading to hallucinations, confusion, or seizures (convulsions). Cardiovascular effects such as a fast or irregular heartbeat and dangerously high blood pressure are also documented. In very young children, there is an increased risk for serious effects, including death, from the misuse of cold and cough products containing these ingredients.

Required Emergency Actions

The regulator-mandated instruction is to seek immediate medical attention or contact a Poison Control Center right away if an overdose is suspected or confirmed. Urgent medical help is required immediately if the individual has severe symptoms such as trouble breathing, loss of consciousness, or has had a seizure. If a severe overdose is confirmed, care typically involves symptomatic and supportive treatment, as no specific antidote is listed in the official labeling. Medical providers will often monitor vital signs, including blood pressure and heart rate, in a clinical setting.

Therapeutic Uses of Stahist AD

What Stahist AD Treats: Main Uses and Benefits

Stahist AD is applied across domains where additional symptomatic support is needed, primarily in situations involving certain distressing symptoms of the upper respiratory system. It is commonly used for managing symptoms associated with the common cold and allergic rhinitis.

This combination product is intended to temporarily relieve symptoms due to the common cold, hay fever (allergic rhinitis), or other upper respiratory allergies. It is relevant in contexts involving heightened systemic burden from both allergic and irritative states.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Dual-Action Support for Heightened Symptom Patterns

This medication is applied in scenarios where symptom clusters may become intense or disruptive, such as seasonal flare-ups or acute cold episodes. It helps address symptoms related to nasal and sinus congestion, runny nose, sneezing, and watery eyes. This supportive relief contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with symptom fluctuations.

Regulatory References

Stahist AD Official Labeling and Indications

Eligibility and Restrictions for Use

Who can and cannot use Stahist AD?

Official regulatory documentation defines eligibility for Stahist AD based on age, co-existing health conditions, and current medication use. Use is contraindicated and absolutely prohibited for several population groups. This includes individuals with a known hypersensitivity to the drug’s components, patients with severe or uncontrolled high blood pressure, or those with severe acute or chronic kidney disease or renal failure.

A major prohibition also applies to anyone currently taking, or within two weeks of stopping, a prescription Monoamine Oxidase Inhibitor (MAOI).

Use is not recommended for children under six years of age, with conditional, limited use only permitted for children aged six to under twelve. Adults and children 12 years and older are approved for standard use.

Furthermore, several pre-existing conditions require conditional use only after consulting a health professional. This includes heart disease, diabetes mellitus, thyroid disease, glaucoma, emphysema or chronic bronchitis, and difficulty urinating due to prostate enlargement. Individuals who are pregnant or breastfeeding are also subject to this conditional use restriction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Stahist AD (Chlorcyclizine/Pseudoephedrine) define clear constraints for co-administration based on documented interaction patterns, focusing on absolute prohibitions and pharmacodynamic reinforcement.

Interaction Type	Interacting Substance Categories	Official Restriction
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Absolute prohibition due to the risk of hypertensive crisis or dangerously high blood pressure.
Pharmacodynamic Reinforcement	CNS Depressants (Sedatives, Tranquilizers); Alcohol	Risk of significant additive central nervous system depression, which may increase the effect of drowsiness.
Sympathomimetic Reinforcement	Other Decongestants; Other Antihistamines	Risk of additive sympathomimetic effects due to the decongestant component, or compounded antihistamine effects.

This profile includes a mandatory timing-based interaction rule: Stahist AD is prohibited for use within 14 days of discontinuing treatment with any MAOI. The interaction with MAOIs is classified as a major risk due to the potentiation of pseudoephedrine’s vascular effects. Separately, the administration of alcohol is restricted, as it is officially documented to increase the effect of drowsiness associated with the antihistamine component. This regulatory structure clearly delineates the substances that are either prohibited or that carry a clinically significant risk of additive effects.

Mechanism of Action

How Stahist AD Works

The physiological action of Stahist AD involves a dual-domain modulation of the histaminergic and adrenergic signaling systems. The active components influence two distinct biological processes that regulate upper airway function.

Targeting the Histaminergic Inflammatory Response

The active component, Chlorcyclizine, acts as a functional antagonist or inverse agonist on the Histamine H1 receptor (, H1 R). By blocking histamine's access to the H1 R, the drug interrupts H1 R-mediated signaling. This action results in a decrease in plasma leakage and tissue fluid accumulation by modulating capillary permeability.

Modulating Nasal Vascular Tone via Adrenergic Signaling

The second active component, Pseudoephedrine, engages the Sympathetic Nervous System (SNS) pathway by primarily activating alpha1-adrenergic receptors (,alpha1 AR) on blood vessels in the nasal lining. This alpha1 AR activation causes vasoconstriction (narrowing of the vessels) and physically reduces the volume of the nasal submucosa.

Functional Coordination of Mechanisms

The two mechanisms are functionally coordinated to modulate the histaminergic signal and the associated vascular response. This simultaneous modulation of two core biological processes influences upper respiratory physiological responses.

Dosage and Administration Information

Stahist AD is an oral medication that must be administered strictly according to the official prescribing information to ensure the correct usage pattern. The medicine is provided as an immediate-release tablet containing 25 mg of Chlorcyclizine HCl and 60 mg of Pseudoephedrine HCl. The overall instruction structure is centered on precise dosing, frequency, and the procedural step to not exceed the approved daily amount.

Instruction Map: How to use Stahist AD — Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral (by mouth).
Dosing Schedule	Adults and Children 12 years and over: 1 tablet per dose.
Frequency	Doses are taken every 6 to 8 hours.
Preparation / Form	The tablet is scored, facilitating administration of the 1/2 tablet dose required for specific pediatric use.
Pediatric Rules	Children 6 to under 12 years: 1/2 tablet per dose.
Maximum Daily Limit	Adults/Children 12 years and over: Not to exceed 3 tablets in 24 hours.

Resulting Procedural Structure

The regulatory usage protocol mandates that the medicine is only taken by mouth on an as-needed schedule, within the designated time frame of 6 to 8 hours between administrations. The primary constraint governing the proper use of the drug is the prohibition against exceeding the established maximum daily dosage for the respective age group, which limits the total intake of the dual components in any 24-hour period. The medicine is officially indicated for the temporary relief of symptoms, thereby defining its short-duration use-context. No preparation beyond the potential dividing of the scored tablet is specified for administration.

Recent Clinical Evidence

Stahist AD: Clinical Research Overview

Stahist AD is a combination product that features an antihistamine (chlorcyclizine) and a nasal decongestant (pseudoephedrine) to address symptoms associated with the common cold, hay fever, and other upper respiratory allergies.

Clinical studies for this type of combination product typically focus on evaluating the temporary relief of symptoms such as:

Rhinorrhea (runny nose)
Nasal congestion (stuffy nose)
Sneezing and itching of the nose or throat
Watery eyes

Key Research Findings (Seasonal Allergic Rhinitis)

Research involving the components of Stahist AD has often been conducted in the context of seasonal allergic rhinitis (hay fever). For instance, a multi-center, randomized, double-blind, placebo-controlled study design has been used to assess the effectiveness and safety profile of formulations containing similar antihistamine and decongestant ingredients over a two-week period. These studies observe changes in patient-reported Total Nasal Symptom Scores (TNSS) compared to a placebo group.

In some trials, the component pseudoephedrine has been compared against placebo for the management of allergic rhinitis symptoms in controlled environments, such as an environmental exposure chamber (EEC) model. This type of setting allows researchers to measure objective markers of congestion, such as changes in the Minimal Cross-Sectional Area (MCA) of the nasal passages, alongside subjective symptom relief.

Overall, the body of evidence supports the temporary, symptomatic relief of allergic and cold-related upper respiratory symptoms when using these established ingredient classes. Researchers continue to assess the clinical profile, particularly the balance between symptomatic relief and potential side effects like drowsiness or cardiovascular changes, in various patient populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Stahist AD (FAQ)

Q: Why is Stahist AD only available behind the counter or by prescription in some places?

One of the active components in Stahist AD is Pseudoephedrine. According to regulatory bodies, this ingredient is subject to federal and state sales restrictions due to its potential use in the illegal manufacture of certain illicit substances. These regulations often require the product to be kept behind the counter or managed by prescription.

Q: Can Stahist AD cause problems with sleep?

Yes, official product information indicates that Stahist AD can potentially affect sleep. The antihistamine component may cause drowsiness, which could impact wakefulness. Conversely, the decongestant component may cause side effects such as nervousness, restlessness, or trouble sleeping (insomnia).

Q: How quickly does Stahist AD start working after taking it?

Regulatory information related to the active components suggests the onset of action is often reported to occur within approximately 40 minutes after administration.

Q: How long does one dose of Stahist AD last?

The recommended interval between doses, as per administration guidelines, is 6 to 8 hours. The effects of the medication are generally aligned with this period.

Q: Do I have to avoid certain foods or drinks while taking Stahist AD?

Official regulatory documents state that the use of alcohol is restricted while taking this medication because it can increase central nervous system side effects like dizziness and drowsiness. The product label states the medicine can be taken with or without food.

Q: Is Stahist AD a steroid?

No, Stahist AD is classified as an Upper Respiratory Combination drug. It contains an antihistamine, Chlorcyclizine, and a decongestant, Pseudoephedrine. It is not described as a steroid in official documents.

Q: Is it normal to feel dry mouth after taking Stahist AD?

Dry mouth is listed in regulatory documents as a common side effect of this medication. This effect is generally associated with the antihistamine component.

Q: Can Stahist AD be used for allergies that aren't related to the nose or sinuses?

The official indication is for the temporary relief of symptoms associated with the common cold, hay fever, and other upper respiratory allergies. The documented purpose is for the temporary relief of upper respiratory and ocular symptoms, such as sneezing, runny nose, and watery eyes.

Q: What should I do if I think I missed a dose of Stahist AD?

Official administration instructions include a protocol for managing missed doses. This protocol involves taking the dose when remembered unless it is nearly time for the next scheduled dose. Regulatory information prohibits taking double or extra doses.

Q: Is Stahist AD used to prevent symptoms or to treat them once they start?

The official indication for this medicine is for the temporary relief of symptoms. This indicates the drug is intended to manage symptoms after they have begun, rather than being used to prevent them.

Q: Is Stahist AD meant to be taken every day, or only when symptoms are active?

The official indication is for temporary, symptomatic relief and the product is intended for use on an as-needed schedule within the recommended dosing limits. This context suggests the product is reactive to symptoms.

Q: Can taking Stahist AD affect the results of an allergy skin test?

Yes, official regulatory and clinical information confirms that this medication may interfere with certain lab tests, specifically including an allergy skin test. This interference may lead to inaccurate results.

Q: Is Stahist AD a controlled substance?

While the product itself is not classified as a controlled drug, one of its active ingredients, Pseudoephedrine, is regulated as a List I chemical. The decongestant component is subject to specific regulatory monitoring and sales restrictions in various jurisdictions.

Q: Are there any known severe or rare side effects of Stahist AD?

Regulatory documents outline potential for serious events which are clinically significant. These include severe reactions like hypertensive crisis (dangerously high blood pressure), cardiovascular collapse, seizures, and fast or irregular heartbeat.

Q: Does Stahist AD interact with common herbal supplements?

Official documentation advises patients to inform a health professional about all products they are currently using, including prescription drugs, nonprescription drugs, and any herbal products or supplements.

Q: What are the guidelines regarding Stahist AD use during pregnancy or breastfeeding?

Regulatory labeling states that individuals who are pregnant or breastfeeding are subject to conditional use restrictions, requiring discussion with a health professional before use. The decongestant component is generally not usually recommended during breastfeeding as it may pass into breast milk and has the potential to decrease milk production.

Q: Is Stahist AD described as having a risk of dependence or addiction?

Regulatory information notes that improper use, or abuse, of this medication may result in serious harm, such as hallucinations or seizure. This is a common way regulators address the non-medical use risk associated with the decongestant component.

Q: Can Stahist AD cause changes in mood or anxiety?

Official documents list side effects that include nervousness and restlessness. In addition, potential mental/mood changes such as confusion or hallucinations are also noted.

Q: Do studies show Stahist AD is helpful for ear pressure or fullness?

Yes, the decongestant component in Stahist AD is officially indicated to help relieve both sinus congestion and pressure, as well as symptoms of ear congestion or fullness.

Q: Is it necessary to take Stahist AD with food?

The medication can be taken with or without food. Taking it with food is listed as an option if stomach upset occurs.

Q: Can Stahist AD be used by people who have diabetes?

The presence of diabetes mellitus is listed in official documents as a condition subject to conditional use restrictions before the medicine is administered. This is related to the fact that the decongestant component has the potential to affect blood glucose concentrations.

Q: What does official data say about Stahist AD use in older adults?

Official data specifies that older adults may be more susceptible to certain adverse effects. These can include increased risk of dizziness, drowsiness, confusion, fast or irregular heartbeat, and difficulty urinating.

Q: Is Stahist AD considered safe to use alongside heart medications?

The product is contraindicated (absolutely prohibited) for use in patients with severe uncontrolled high blood pressure or severe coronary artery disease. Furthermore, regulatory information notes that the decongestant component must be administered with caution in individuals with underlying cardiovascular disorders, given the risk of increased heart rate and blood pressure.

Q: What should be done if someone experiences a serious side effect from Stahist AD?

Official documents describe that if serious effects occur, such as seizure or a fast/uneven heart rate, the administration of the medicine should be discontinued. These documents also specify that in the event of an overdose or serious reaction, external help (such as emergency services or a Poison Control Center) must be contacted immediately.

Q: Does Stahist AD contain latex or common allergens?

The official label contains a warning that the product may contain inactive ingredients which can cause allergic reactions in sensitive individuals. The complete list of inactive ingredients must be reviewed for specific allergens.

Q: What is the list of inactive ingredients in Stahist AD?

The regulatory labeling includes a complete list of inactive ingredients. Common components found in this list include substances such as Crospovidone, Cellulose, Magnesium Stearate, and various coloring agents.

Q: Does Stahist AD contain sugar or gluten?

Regulatory documents list the inactive ingredients and advise that patients who have a medical condition requiring them to limit or avoid certain substances in their diet should review this full list. Specific labeling for 'sugar' or 'gluten' may not be universally provided.

How should Stahist AD be stored and disposed of?

Storage and Disposal Instructions for Stahist AD

Stahist AD must be stored according to official regulatory requirements to maintain the integrity of the medication.

Mandatory Storage Conditions

Item	Requirement
Temperature	Store at room temperature.
Environmental Protection	Must be protected from light and moisture.
Child Safety	Mandatory to keep out of the reach of children.

Official Disposal Procedures

Disposal of unused or expired Stahist AD should follow approved regulatory guidelines. This involves using a drug take-back program or adhering to the official household trash mixing procedure. The product must not be flushed down a toilet or poured down a drain, as instructed by health authorities.

Stahist AD